International provider of SaaS-based track and trace and serialisation solutions, rfxcel, today announces its continued successful expansion in the UK and EMEA, with triple digit percentage revenue growth since 2017. Increasing numbers of pharmaceutical companies welcome rfxcel’s inclusive approach to helping its clients successfully achieve the EMVO (European Medicines Verification Organisation) onboarding process as part of their compliance with the Falsified Medicines Directive (FMD).

rfxcel now boasts on-the-ground sales, delivery and customer support teams across four continents, including its US headquarters, an EMEA head office in the UK, and bases in Latin America, India and Japan as well as local capability in Russia. Sales headcount has increased by 300% and delivery and support teams by 350% over the same period. Working relationships with major global business partners have also been established, further extending rfxcel’s complementary offerings.

Mark Davison, rfxcel Senior Director of Operations Europe, comments: "rfxcel prides itself on our rapid, full-service implementation model, which provides a great opportunity to marketing authorisation holders (MAHs) who need move quickly.  With the February 2019 FMD deadline rapidly approaching, companies are recognising that they need an experienced provider who can not only support them through the initial implementation but will go the extra mile to ensure the success of their solution, from data integrity to testing the end-to-end connectivity, reporting and interaction with business partners. Many customers have already registered rfxcel as their EMVO provider.  With our established links to the European Medicines Verification System (EMVS) for MAHs, as well as national systems (NMVSs) for distributors and dispensers, we provide an award-winning solution for the whole supply chain impacted by FMD."

Mark Davison further comments: "As an additional benefit, rfxcel’s full-service implementation model, enables companies to also avoid the hidden costs and additional resources required by other solution providers to onboard their trading partners."

Glenn Abood, Chairman and CEO, rfxcel, adds: "Patient safety is at risk if people can’t verify the validity of the drug. rfxcel’s aim is to help the global pharmaceutical industry mitigate that risk and protect their patients and products. With integrity at the heart of our business – from helping clients with their data integrity, to our commitment to our customers – we help secure the supply chain, bring visibility in product distribution, enable compliance with government regulations, and ensure patient safety. We are immensely proud that this is an ethos that is being recognised and welcomed by the industry."

On 20th June 2018, rfxcel is hosting a webinar entitled: ‘The EU Falsified Medicines Directive: Data Integrity in a Serialised World’, covering aspects of FMD compliance including why data integrity is only as good as the weakest link; how data errors can occur in validated systems; why active error checking is needed; what the regulators are planning; and how organisations can prepare.

For more information or to learn more about the requirements surrounding the European Union’s Falsified Medicines Directive (FMD) or rfxcel’s solutions to meet these needs, please contact us.